SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AQUILA BIOPHARMACEUTICALS INC (AQLA) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (30)5/3/2000 9:36:00 AM
From: Harry J.  Respond to of 45
 
TD - The news release only discussed S. aureus results. The Annual Report (pg. 6) said the tested vaccine also had an E. coli component. Wonder if AQLA can compete in the E.coli vaccine market with a "non-bivalent" vaccine . . .

Regards,
Harry J.



To: Arthur Radley who wrote (30)5/3/2000 10:01:00 AM
From: AurumRabosa  Respond to of 45
 
First I needed a defibrillator ;-(
Well so much for the idea that in testing drugs on animals they know something about efficacy before conducting final trials.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News